{"id":"keverprazan-14-days","safety":{"commonSideEffects":[{"rate":"null","effect":"dizziness"},{"rate":"null","effect":"cough"},{"rate":"null","effect":"hypotension"}]},"_chembl":{"chemblId":"CHEMBL267665","moleculeType":"Small molecule","molecularWeight":"285.30"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Direct renin inhibitors are a class of drugs that block the action of renin, an enzyme involved in the renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure and fluid balance. By inhibiting renin, keverprazan reduces the production of angiotensin I and II, leading to vasodilation and decreased blood pressure.","oneSentence":"Keverprazan is a direct renin inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:02.256Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT06734260","phase":"PHASE3","title":"Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Eighth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-09-10","conditions":"Helicobacter Pylori Eradication Rate","enrollment":477},{"nctId":"NCT07122024","phase":"PHASE4","title":"Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-02-19","conditions":"Helicobacter Pylori","enrollment":414},{"nctId":"NCT06851468","phase":"NA","title":"Keverprazan Combined with Amoxicillin for the Treatment of Helicobacter Pylori","status":"NOT_YET_RECRUITING","sponsor":"Key Laboratory for Gastrointestinal Diseases of Gansu Province","startDate":"2025-03-15","conditions":"Helicobacter Pylori","enrollment":264},{"nctId":"NCT06777732","phase":"EARLY_PHASE1","title":"The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2025-03","conditions":"Helicobacter Pylori Infection","enrollment":672},{"nctId":"NCT06760065","phase":"PHASE3","title":"Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-01-15","conditions":"Helicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education","enrollment":316},{"nctId":"NCT06412640","phase":"PHASE4","title":"Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-06-01","conditions":"H. Pylori Infection","enrollment":268}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Amoxicillin"],"phase":"marketed","status":"active","brandName":"Keverprazan 14 days","genericName":"Keverprazan 14 days","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Keverprazan is a direct renin inhibitor. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}